Molecular and serological investigation of the 2021 COVID-19 case surge in **Mongolian vaccinees** Naranjargal J. Dashdorj; PhD<sup>1</sup>, Naranbaatar D. Dashdorj; PhD<sup>1#</sup>, Mitali Mishra; PhD<sup>2</sup>, Lisa Danzig; *MD*<sup>3</sup>, Thomas Briese; *PhD*<sup>2</sup>, W. Ian Lipkin; *MD*<sup>2#\$</sup>, Nischay Mishra; *PhD*<sup>2#\$</sup> <sup>1</sup>Onom Foundation, Ulaanbaatar, Mongolia <sup>2</sup>Center for Infection and Immunity, Columbia University, New York, USA <sup>3</sup> PANDEFENSE Advisory, USA <sup>#</sup>corresponding authors <sup>\$</sup>NM and WIL equally contributed Corresponding author (s) Nischay Mishra, PhD, email: nm2641@cumc.columbia.edu W. Ian Lipkin, MD, email: wil2001@cumc.columbia.edu Naranbaatar D. Dashdorj, PhD, email: nd@onomfoundation.org Word count: 591 Table: 1 Figure: 1 

#### 46 Abstract

47 A surge in Covid-19 cases in Mongolia in March 2021 resulted in a governmentmandated shutdown. This shutdown was relaxed in May 2021 as case numbers 48 49 decreased and nationwide vaccination rates using Sinopharm, Covishield/AstraZeneca, Sputnik V, and Pfizer/BioNTech vaccines exceeded 50% of the population. Case rates 50 increased again in early June 2021 in both vaccinated and non-vaccinated individuals. 51 52 To determine whether the surge was due to the emergence of Delta or another variant, 53 or vaccine failure, a rapid, opportunistic investigation was conducted that comprised virus sequence analysis of nasal swab samples from breakthrough cases and antibody 54 55 assays of plasma from healthy vaccinees. More than 90% of breakthrough infections during the second case surge were due to the Alpha variant. Spike protein ELISA and 56 SARS-CoV-2 neutralization assays data revealed large differences in plasma titers of 57 antibodies to SARS-CoV-2, with mRNA vaccines eliciting higher titers than adenovirus-58 59 vectored or killed virus vaccines.

60

#### 61 Introduction

In March 2021 an increase in COVID-19 cases in Mongolia (population 3.3 million) led to a government-mandated shutdown and a nationwide vaccination program with four different vaccines. In early June, a reduction in cases attributed to vaccination led to relaxation of the shutdown that was followed by a surge in disease (Figure. 1).

To determine whether the surge was due to the emergence of Delta or another variant, or vaccine failure, a rapid, opportunistic investigation was conducted that comprised virus sequence analysis of nasal swab samples from breakthrough cases and antibody assays of plasma from healthy vaccinees.

71

# 72 Methods

73 Samples were collected with informed consent. RNA from nasal swabs was extracted 74 for Illumina sequencing using the Mybaits capture system (Arbor Biosciences). Reads were mapped and aligned to SARS-CoV-2 reference sequence (accession no. 75 NC\_045512) and variant analyses performed using GISAID, NextClade[1]. Plasma from 76 77 healthy vaccinees were screened for anti-SARS-CoV-2 antibodies in EUROIMMUN 78 Anti-SARS-CoV-2 IgG ELISA and EUROIMMUN Anti-SARS-CoV-2 NCP IgG ELISA. 79 Neutralizing antibodies (NAb) to Washington, and Delta SARS-CoV-2 variants were 80 quantitated in an absolute end point neutralization assay that measures 100% 81 neutralizing activity with a SARS-CoV-2 gPCR [2]. 82

# 83 Results

We sequenced 97 nasal samples from Covid-19 patients with breakthrough infections after vaccination (Supplementary Table 1), and tested plasma from 100 healthy subjects for antibodies to SARS-CoV-2 (surface glycoprotein, S and nucleocapsid phosphoprotein, NCP), and NAb after Covishield/AstraZeneca, Sputnik V, Sinopharm, or Pfizer/BioNTech vaccination (Table 1).

Full-length SARS-CoV-2 sequences were obtained from 92 samples. Eighty-seven of 92 (94.6%) were Alpha variant. Five of 92 (5.4%) were Delta variant. Of 87 Alpha

91 variant breakthrough infections, 54 (62.1 %) were from Sinopharm, 7 (8.0%) from

Sputnik V, 23 (26.4%) from Covishield/AZN, and 3 (3.4%) from Pfizer/BioNTech
vaccinees. Of 5 breakthrough Delta variant infections, 1 (20%) was from Sinopharm, 3
(60%) were from Covishield/AZN, and 1 (20%) was from Pfizer/BioNTech vaccinees
(Supplementary Table 1).

96 More subjects had spike ELISA reactivity after Pfizer/BioNTech (91.6%), and 97 Covishield/AstraZeneca (70.8%), than Sputnik V (29.2%) or Sinopharm (12.5%). 98 Nucleoprotein reactivity was present in 12.5% of Sinopharm vaccinees. One 99 Covishield/AstraZeneca vaccinee was NP positive, presumably because of infection. Only Sinopharm contains NP. Three of four subjects (75%) who received two 100 101 Sinopharm doses followed by one Pfizer/BioNTech dose were spike-positive (Table 1) (Supplemental Figure 1). More subjects had NAb to WA strain after Pfizer/BioNTech 102 103 (79.7%), and Covishield/AstraZeneca (50.0%), than after Sputnik V (25.0%) or 104 Sinopharm (20.8%). Neutralizing antibodies to Delta variants were present in fewer subjects after Pfizer/BioNTech (29.2%), Sputnik V (8.33%), and Sinopharm (12.5%). 105 106 NAb to Delta variants were detected in nine subjects after Covishield/AZN (37.50%); 107 however, 3/9 were NCP ELISA-positive indicating previous SARS-CoV-2 exposure. 108 Eliminating these three subjects would decrease the percentage with NAb to Delta to 109 25%. Three of four vaccinees who received a single dose of Pfizer/BioNTech after two 110 doses of Sinopharm had NAb to WA; one had NAb to Delta.

111

# 112 **Discussion**

113 Our findings provide additional support for ordinal hierarchy of protection amongst 114 vaccine platforms, with mRNA vaccines performing better than adenovirus-vectored or killed virus vaccines [3]. They also confirm that current vaccines, based on the 115 116 prototypic WA strain, elicit only minimal levels of NAb to current circulating strains [4 5]. 117 The case surge in Mongolia in June 2021 did not reflect the introduction of the Delta variant but premature relaxation of physical distancing and masking. These findings 118 119 underscore the importance of continuous surveillance for virus evolution, coordinated 120 modification of vaccines, and a cautious approach to the elimination of classical social 121 controls for mitigating contagion.

122

# 123 Limitations

- 124 Our study was limited in numbers and in its retrospective collection of specimens.
- 125

# 126 **Figure Legend:**

127

128 Figure 1. A] Time line of COVID-19 in Mongolia February 2020 - July 2021; B]

129 Illustration of daily new cases in Mongolia with 3 days and seven days moving average 130 of daily new cases (blue plot lines) Source:

- 131 https://www.worldometers.info/coronavirus/country/mongolia/
- 132

**Table 1:** SARS-CoV-2 immunoreactivity of plasma samples from 100 healthy vaccinated individuals as determined by S-ELISA, NCP-ELISA, and end point absolute viral neutralization assay against WA strain and Delta variant. Samples were collected with informed consent under the auspices of Onom IRB 241 and IRB 242.

137

#### 138 **Article Information**

- 139 **Corresponding Authors:** Nischay Mishra, PhD, ND Dashdorj, and W. Ian Lipkin, MD
- 140

141 Author Contributions: Dr. Mishra & Dr. Lipkin had full access to all of the data in the

- 142 study and takes responsibility for the integrity of the data and the accuracy of the data 143 analysis. 144
- 145 Concept and design: Mishra, Lipkin, Danzig, Nara Dashdorj, and ND Dashdorj
- 146

150

- 147 Acquisition, analysis, or interpretation of data: All authors.
- 148 149 Drafting of the manuscript: Mishra, Lipkin
- 151 Critical revision of the manuscript for important intellectual content: All authors.
- 152 153 Statistical analysis: Mishra, Lipkin
- 154
- 155 Obtained funding: Lipkin
- 156
- 157 Administrative, technical, or material support: Mishra, Lipkin, Nara Dashdorj, and ND 158 Dashdorj 159
- 160 Supervision: Mishra, Briese, Lipkin
- 161 162 Conflict of Interest Disclosures: None

163 164 Funding/Support: This study was funded by the Skoll Foundation and the Onom Foundation. 165

166

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the 167 168 study; collection, management, analysis, and interpretation of the data; preparation, 169 review, or approval of the manuscript; and decision to submit the manuscript for 170 publication.

171

172 Additional Contributions: Nancy Messonnier; MD (Skoll Foundation) and Larry 173 Brilliant; MD(Pandefense) provided insights into study design. We are grateful to CII 174 staff members; Komal Jain; MS for bioinformatics analyses, Lokendra Chauhan; MS and 175 Eliza Choi: MS for neutralization assays, Riddhi Thakkar: BS for ELISA assays, James 176 Ng;BS for RNA extractions and gPCRs, Alexandra Oleynik Petrosov; MS and Alper Gokden; MS for high throughput sequencing, and Pryanka Sharma; MS for sample 177 178 shipment and logistics. We would like to thank Sumiya Byambabaatar; MS, Purevjargal Bat-Ulzii, Anir Enkhbat, Enkhtuul Batbold, Delgersaikhan Zulkhuu, Byambasuren 179 Ochirsum, Tungalag Khurelsukh, Ganbold Dalantai, Natsagdorj Burged, Uurtsaikh 180 Baatarsuren, Nomin Ariungerel, Odgerel Oidovsambuu, Andreas S. Bungert, Zulkhuu 181 182 Genden, Dahgwahdorj Yagaanbuyant, and Altankhuu Mordorj for sample collection and administrative support. 183

| 184 |   |
|-----|---|
| 185 |   |
| 186 | 1. Abdalhamid B, Iwen PC, Wiley MR, Pratt CB, Hinrichs SH. Genome Analysis for Sequence           |
| 187 | Variants in SARS-CoV-2 Among Asymptomatic Individuals in a Long-term Care Facility.               |
| 188 | JAMA Netw Open 2021; <b>4</b> (4):e217939 doi:  |
| 189 | 10.1001/jamanetworkopen.2021.7939[published Online First: Epub Date] .                            |
| 190 | 2. Eckhardt CM, Cummings MJ, Rajagopalan KN, et al. Evaluating the efficacy and safety of         |
| 191 | human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A                 |
| 192 | structured summary of a study protocol for a randomized controlled trial. Trials                  |
| 193 | 2020; <b>21</b> (1):499 doi: 10.1186/s13063-020-04422-y[published Online First: Epub Date] .      |
| 194 | 3. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 Vaccines. JAMA 2021; <b>325</b> (13):1318-20 doi: |
| 195 | 10.1001/jama.2021.3199[published Online First: Epub Date] .                                       |
| 196 | 4. Tada T, Zhou H, Samanovic MI, et al. Comparison of Neutralizing Antibody Titers Elicited by    |
| 197 | mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants. bioRxiv 2021 doi:                 |
| 198 | 10.1101/2021.07.19.452771[published Online First: Epub Date] .                                    |
| 199 | 5. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the      |
| 200 | B.1.617.2 (Delta) Variant. N Engl J Med 2021 doi: 10.1056/NEJMoa2108891[published                 |
| 201 | Online First: Epub Date] .  |
| 202 |   |



| Serological<br>assay       | Status         | Pfizer/BioNTech<br>(n=24) | Covishield/AZN<br>(n=24) | Sputnik V<br>(n=24) | Sinopharm<br>(n=24) | Sinopharm +<br>Pfiz/BioN*<br>(n=4) | chi-square test significant (<0.05)<br><i>p</i> values (total positive vs<br>negative)   |
|----------------------------|----------------|---------------------------|--------------------------|---------------------|---------------------|------------------------------------|--|
| Spike ELISA                | Negative       | 0 (0.00%)                 | 5 (20.83%)               | 12 (50%)            | 17 (70.83%)         | 0 (0.00%)                          | Pfizer/BioNTech vs Sputnik V=0.0002,<br>Pfizer/BioNTech vs Sinopharm=0.0001,<br>Covishield/AZN vs Sputnik V=0.03,<br>Covishield/AZN vs Sinopharm=0.0005      |
|                            | Total positive | 24 (100.00)               | 19 (79.17%)              | 12 (50%)            | 7 (29.17%)          | 4 (100%)                           |  |
|                            | Weak positive  | 2 (8.33%)                 | 2 (8.33%)                | 5 (20.83%)          | 4 (16.67%)          | 1 (25.00%)                         |  |
|                            | Positive       | 22 (91.67%)               | 17 (70.83%)              | 7 (29.17%)          | 3 (12.5%)           | 3 (75.00%)                         |  |
|                            | Negative       | 23 (95.83%)               | 21 (87.50%)              | 23 (95.83%)         | 21 (87.5%)          | 3 (75.00%)                         | - NA   |
|                            | Total positive | 1 (4.17%)                 | 3 (12.50%)               | 1 (4.17%)           | 3 (12.5%)           | 1 (25.00%)                         |  |
| NCP ELISA                  | Weak positive  | 1 (4.17%)                 | 2 (8.33%)                | 0 (0.00%)           | 0 (0.00%)           | 0 (0.00%)                          |  |
|                            | Positive       | 0 (0.00%)                 | 1 (4.17%)                | 1 (4.17%)           | 3 (12.5%)           | 1 (25.00%)                         |  |
| Neutralizing<br>Ab (WA)    | Not detected   | 5 (20.83%)                | 12 (50.0%)               | 18 (75.00%)         | 19 (79.17%)         | 1 (25.00%)                         | Pfizer/BioNTech vs Covishield/AZN=0.03,<br>Pfizer/BioNTech vs Sputnik V=0.0002,<br>Pfizer/BioNTech vs Sinopharm=0.00005,<br>Covishield/AZN vs Sinopharm=0.03 |
|                            | Detected       | 19 (79.17%)               | 12 (50.0%)               | 6 (25.00%)          | 5 (20.83%)          | 3 (75.00%)                         |  |
|                            | ≤1:40          | 14 (58.30%)               | 4 (16.70%)               | 4 (16.70%)          | 2 (8.33%)           | 2 (50.00%)                         |  |
|                            | ≥1:40          | 5 (20.83%)                | 8 (33.30%)               | 2 (8.33%)           | 3 (12.50%)          | 1 (25.00%)                         |  |
| Neutralizing<br>Ab (Delta) | Not detected   | 17 (70.83%)               | 15 (62.50%)              | 22 (91.6%)          | 21 (87.5%)          | 3 (75.00%)                         | Covishield/AZN vs Sputnik V=0.016,<br>Covishield/AZN vs Sinopharm=0.045  |
|                            | Detected       | 7 (29.17%)                | 9 (37.50%)               | 2 (8.33%)           | 3 (12.5%)           | 1 (25.00%)                         |  |
|                            | ≤1:40          | 4 (16.67%)                | 3 (12.50%)               | 1 (4.20%)           | 2 (8.33%)           | 0 (0.00%)                          |  |
|                            | ≥1:40          | 3 (12.50%)                | 6 (25.00%)               | 1 (4.20%)           | 1 (4.20%)           | 1 (25.00%)                         |  |

\*Sinopharm + Pfiz/BioN group was not included in statistical analysis due to small sample size. NA- No significant (<.05) p value was recorded for NCP ELISA.

Table 1: SARS-CoV-2 immunoreactivity of plasma samples from 100 healthy vaccinated individuals; as determined by S-ELISA, NCP-ELISA, and end point absolute viral neutralization assay against WA strain and Delta variant. Samples were collected with informed consent under the auspices of Onom IRB 241 and IRB 242.